scholarly journals Combination of Antifungal Drugs and Protease Inhibitors Prevent Candida albicans Biofilm Formation and Disrupt Mature Biofilms

2020 ◽  
Vol 11 ◽  
Author(s):  
Matthew B. Lohse ◽  
Megha Gulati ◽  
Charles S. Craik ◽  
Alexander D. Johnson ◽  
Clarissa J. Nobile
2020 ◽  
Author(s):  
Matthew B. Lohse ◽  
Megha Gulati ◽  
Charles S. Craik ◽  
Alexander D. Johnson ◽  
Clarissa J. Nobile

AbstractBiofilms formed by the fungal pathogen Candida albicans are resistant to many of the antifungal agents commonly used in the clinic. Previous reports suggest that protease inhibitors, specifically inhibitors of aspartyl proteases, could be effective antibiofilm agents. We screened three protease inhibitor libraries, containing a total of 80 compounds for the abilities to prevent C. albicans biofilm formation and to disrupt mature biofilms. The compounds were screened individually and in the presence of subinhibitory concentrations of the most commonly prescribed antifungal agents for Candida infections: fluconazole, amphotericin B, or caspofungin. Although few of the compounds affected biofilms on their own, seven aspartyl protease inhibitors inhibited biofilm formation when combined with amphotericin B or caspofungin. Furthermore, nine aspartyl protease inhibitors disrupted mature biofilms when combined with caspofungin. These results suggest that the combination of standard antifungal agents together with specific protease inhibitors may be useful in the prevention and treatment of C. albicans biofilm infections.ImportanceCandida albicans is one of the most common pathogens of humans. C. albicans forms biofilms, structured communities of cells several hundred microns thick, on both biotic and abiotic surfaces. These biofilms are typically resistant to antifungal drugs at the concentrations that are normally effective against free-floating cells, thus requiring treatment with higher drug concentrations that often have significant side effects. Here, we show that certain combinations of existing antifungal agents with protease inhibitors, including several drugs already commonly used to treat HIV patients, are effective at inhibiting biofilm formation by C. albicans and/or at disrupting mature C. albicans biofilms.


Author(s):  
Gunderao Hanumantrao Kathwate ◽  
Ravikumar Bapurao Shinde ◽  
S. Mohan Karuppayil

2021 ◽  
Vol 9 (3) ◽  
pp. 500 ◽  
Author(s):  
Priyanka Bapat ◽  
Gurbinder Singh ◽  
Clarissa J. Nobile

Fungal infections are increasing in prevalence worldwide, especially in immunocompromised individuals. Given the emergence of drug-resistant fungi and the fact that there are only three major classes of antifungal drugs available to treat invasive fungal infections, there is a need to develop alternative therapeutic strategies effective against fungal infections. Candida albicans is a commensal of the human microbiota that is also one of the most common fungal pathogens isolated from clinical settings. C. albicans possesses several virulence traits that contribute to its pathogenicity, including the ability to form drug-resistant biofilms, which can make C. albicans infections particularly challenging to treat. Here, we explored red, green, and blue visible lights alone and in combination with common photosensitizing compounds for their efficacies at inhibiting and disrupting C. albicans biofilms. We found that blue light inhibited biofilm formation and disrupted mature biofilms on its own and that the addition of photosensitizing compounds improved its antibiofilm potential. Red and green lights, however, inhibited biofilm formation only in combination with photosensitizing compounds but had no effects on disrupting mature biofilms. Taken together, these results suggest that photodynamic therapy may be an effective non-drug treatment for fungal biofilm infections that is worthy of further exploration.


2017 ◽  
Vol 14 (4) ◽  
pp. 1503-1511 ◽  
Author(s):  
Renuka R. Goswami ◽  
Suhas D. Pohare ◽  
Jayant S. Raut ◽  
S. Mohan Karuppayil

ABSTRACT: Cell surface hydrophobicity (CSH) is one of the important virulence attributes which helps Candida albicans to be a successful fungal pathogen. It influences several steps in pathogenesis of C. albicans leading to establishment of infection. CSH plays an important role in adhesion of cells to host tissues and catheters/medical devices implanted in patients. Adhesion to surfaces and subsequent biofilm formation are crucial because it may result in resistance to antifungal drugs. This important pathogenicity determinant would also be an attractive antifungal target. Various studies indicate that antifungal drugs tend to lower the CSH of Candida cells. Interestingly, molecules of plant origin have been reported to modulate CSH, reduce adhesion and interfere in biofilm formation by C. albicans. The review presents a brief account of biochemical basis of CSH, its role in adhesion and biofilm formation by C. albicans as well as explores it as an antifungal drug target.


2021 ◽  
Author(s):  
Xin Liu ◽  
Lili Zhong ◽  
Zhiming Ma ◽  
Yujie Sui ◽  
Jia’nan Xie ◽  
...  

AbstractThe human fungal pathogen Candida albicans can cause many kinds of infections, including biofilm infections on medical devices, while the available antifungal drugs are limited to only a few. In this study, alantolactone (Ala) demonstrated antifungal activities against C. albicans, as well as other Candida species, with a MIC of 72 μg/mL. Ala could also inhibit the adhesion, yeast-to-hyphal transition, biofilm formation and development of C. albicans. The exopolysaccharide of biofilm matrix and extracellular phospholipase production could also be reduced by Ala treatment. Ala could increase permeability of C. albicans cell membrane and ROS contribute to the antifungal activity of Ala. Overall, the present study suggests that Ala may provide a promising candidate for developing antifungal drugs against C. albicans infections.


Genes ◽  
2018 ◽  
Vol 9 (11) ◽  
pp. 540 ◽  
Author(s):  
Pei Chong ◽  
Voon Chin ◽  
Won Wong ◽  
Priya Madhavan ◽  
Voon Yong ◽  
...  

Candida albicans is an opportunistic fungal pathogen, which causes a plethora of superficial, as well as invasive, infections in humans. The ability of this fungus in switching from commensalism to active infection is attributed to its many virulence traits. Biofilm formation is a key process, which allows the fungus to adhere to and proliferate on medically implanted devices as well as host tissue and cause serious life-threatening infections. Biofilms are complex communities of filamentous and yeast cells surrounded by an extracellular matrix that confers an enhanced degree of resistance to antifungal drugs. Moreover, the extensive plasticity of the C. albicans genome has given this versatile fungus the added advantage of microevolution and adaptation to thrive within the unique environmental niches within the host. To combat these challenges in dealing with C. albicans infections, it is imperative that we target specifically the molecular pathways involved in biofilm formation as well as drug resistance. With the advent of the -omics era and whole genome sequencing platforms, novel pathways and genes involved in the pathogenesis of the fungus have been unraveled. Researchers have used a myriad of strategies including transcriptome analysis for C. albicans cells grown in different environments, whole genome sequencing of different strains, functional genomics approaches to identify critical regulatory genes, as well as comparative genomics analysis between C. albicans and its closely related, much less virulent relative, C. dubliniensis, in the quest to increase our understanding of the mechanisms underlying the success of C. albicans as a major fungal pathogen. This review attempts to summarize the most recent advancements in the field of biofilm and antifungal resistance research and offers suggestions for future directions in therapeutics development.


2018 ◽  
Vol 13 (12) ◽  
pp. 1934578X1801301
Author(s):  
Tristia Rinanda ◽  
Rizki Puji Isnanda ◽  
Zulfitri

Biofilm formation is one of the virulence factors of Candida albicans, contributing to the development of resistance to various antifungal drugs. In order to combat resistant microbes such as C. albicans, the discovery and development of antifungal substances must explore the anti-biofilm activity of substances, which are extracted from traditional medicinal plants widely available in tropical countries such as Indonesia. One of the natural ingredients that can be developed is red ginger. This plant has been used empirically in the treatment of various infectious diseases, including fungal infections. The aim of this study is to determine the composition of chemical compounds in the essential oil of the red ginger rhizomes planted in Aceh, Indonesia and the anti-biofilm activity of the essential oil against C. albicans, isolated from a clinical sample. The chemical analysis of the essential oil was performed by Gas Chromatography-Mass Spectrophotometry (GC-MS). Anti-biofilm activity was observed through biofilm inhibition and degradation activities, determined by Cristal Violet assay. Data were analyzed using ANOVA test and Duncan's post hoc test with 99% CI. The GC-MS results showed that the essential oil used in this study contained high monoterpenes (60.55%) which is dominated by E-citral/geranial (11.97%) and 1.8 - cineole (15.10%). The highest sesquiterpenes derivative was αr-curcumene (16.86%). The significant inhibition of C. albicans biofilm formation was obtained at a concentration of 0.5% and the biofilm degradation was obtained at a concentration of 0.125%. The data indicates that the high monoterpenoids-red ginger essential oil used in this study has performed significant anti-biofilm activity against C. albicans.


2013 ◽  
Vol 57 (8) ◽  
pp. 3681-3687 ◽  
Author(s):  
Samuel A. Siles ◽  
Anand Srinivasan ◽  
Christopher G. Pierce ◽  
José L. Lopez-Ribot ◽  
Anand K. Ramasubramanian

ABSTRACTCandida albicansis the most common etiologic agent of systemic fungal infections with unacceptably high mortality rates. The existing arsenal of antifungal drugs is very limited and is particularly ineffective againstC. albicansbiofilms. To address the unmet need for novel antifungals, particularly those active against biofilms, we have screened a small molecule library consisting of 1,200 off-patent drugs already approved by the Food and Drug Administration (FDA), the Prestwick Chemical Library, to identify inhibitors ofC. albicansbiofilm formation. According to their pharmacological applications that are currently known, we classified these bioactive compounds as antifungal drugs, as antimicrobials/antiseptics, or as miscellaneous drugs, which we considered to be drugs with no previously characterized antifungal activity. Using a 96-well microtiter plate-based high-content screening assay, we identified 38 pharmacologically active agents that inhibitC. albicansbiofilm formation. These drugs were subsequently tested for their potency and efficacy against preformed biofilms, and we identified three drugs with novel antifungal activity. Thus, repurposing FDA-approved drugs opens up a valuable new avenue for identification and potentially rapid development of antifungal agents, which are urgently needed.


2018 ◽  
Vol 2018 ◽  
pp. 1-13 ◽  
Author(s):  
Longfei Yang ◽  
Xin Liu ◽  
Xinming Zhuang ◽  
Xuechao Feng ◽  
Lili Zhong ◽  
...  

Candida albicans is the most common fungal pathogen causing serious diseases, while there are only a paucity of antifungal drugs. Therefore, the present study was performed to investigate the antifungal effects of saponin extract from rhizomes of Dioscorea panthaica Prain et Burk (Huangshanyao Saponin extract, HSE) against C. albicans. HSE inhibits the planktonic growth and biofilm formation and development of C. albicans. 16–64 μg/mL of HSE could inhibit adhesion to polystyrene surfaces, transition from yeast to filamentous growth, and production of secreted phospholipase and could also induce endogenous reactive oxygen species (ROS) production and disrupt cell membrane in planktonic cells. Inhibitory activities against extracellular exopolysaccharide (EPS) production and ROS production in preformed biofilms could be inhibited by 64–256 μg/mL of HSE. Cytotoxicity against human Chang’s liver cells is low, with a half maximal inhibitory concentration (IC50) of about 256 μg/mL. In sum, our study suggested that HSE might be used as a potential antifungal therapeutic against C. albicans.


2015 ◽  
Vol 59 (12) ◽  
pp. 7611-7620 ◽  
Author(s):  
Taissa Vieira Machado Vila ◽  
Ashok K. Chaturvedi ◽  
Sonia Rozental ◽  
Jose L. Lopez-Ribot

ABSTRACTThe generation of a new antifungal againstCandida albicansbiofilms has become a major priority, since biofilm formation by this opportunistic pathogenic fungus is usually associated with an increased resistance to azole antifungal drugs and treatment failures. Miltefosine is an alkyl phospholipid with promising antifungal activity. Here, we report that, when tested under planktonic conditions, miltefosine displays potentin vitroactivity against multiple fluconazole-susceptible and -resistantC. albicansclinical isolates, including isolates overexpressing efflux pumps and/or with well-characterized Erg11 mutations. Moreover, miltefosine inhibitsC. albicans biofilm formation and displays activity against preformed biofilms. Serial passage experiments confirmed that miltefosine has a reduced potential to elicit resistance, and screening of a library ofC. albicanstranscription factor mutants provided additional insight into the activity of miltefosine againstC. albicansgrowing under planktonic and biofilm conditions. Finally, we demonstrate thein vivoefficacy of topical treatment with miltefosine in the murine model of oropharyngeal candidiasis. Overall, our results confirm the potential of miltefosine as a promising antifungal drug candidate, in particular for the treatment of azole-resistant and biofilm-associated superficial candidiasis.


Sign in / Sign up

Export Citation Format

Share Document